Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) ...
Zacks Investment Research on MSN
Plus Therapeutics (PSTV) reports Q1 loss, tops revenue estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to a loss of $14 per share a year ago. These figures ...
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin ...
HOUSTON (AP) — HOUSTON (AP) — Plus Therapeutics, Inc. (PSTV) on Friday reported a loss of $6.9 million in its first quarter. The Houston-based company said it had a loss of $1.05 per share. The ...
HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform ...
The average one-year price target for Plus Therapeutics (NasdaqCM:PSTV) has been revised to $38.76 / share. This is a decrease of 72.34% from the prior estimate of $140.15 dated April 12, 2026. The ...
HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and ...
cGMP production of 186RNL targeted radiotherapeutic beginning in second half of 2022 to support ongoing and future ReSPECT™ clinical trials The FDA indicated agreement with the Company’s proposed ...
The oral presentation, titled, “¹⁸⁶Rhenium-Nanoliposomes (¹⁸⁶RNL) for the Treatment of Leptomeningeal Metastases: Translational Insights from Clinical and Preclinical Models,” was delivered by ...
Detailed price information for Plus Therapeutics Inc (PSTV-Q) from The Globe and Mail including charting and trades.
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results